Advanced Therapies: Invention or Innovation?
-
By
-
Liam Tremble
-
September 23, 2026
-
7 min
Clinical Report: Advanced Therapies: Invention or Innovation?
Background
Advanced therapies, including cell therapies, represent significant advancements in treating late-stage cancers and genetic diseases. However, their scalability and accessibility remain major concerns, particularly in diverse healthcare infrastructures.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
- Cell therapies have shown potential for curative outcomes in late-stage treatment refractory cancers.
- Less than 20% of cancer patients in the USA are treated in large hospitals, contrasting with Europe where most patients are treated in such settings.
- Emerging therapies like bispecific antibodies are associated with severe hematological toxicities, requiring extended hospital stays for some patients.
- There is a global movement to broaden access to advanced therapies, particularly in community settings.
- Educational programs are essential for training healthcare providers to manage patients receiving advanced therapies.
Clinical Implications
Healthcare providers must be aware of the logistical and educational challenges associated with administering advanced therapies.
Conclusion
The successful integration of advanced therapies into clinical practice requires addressing scalability and accessibility.
Related Resources & Content
- The Medicine Maker, Innovation Returns, 2016 -- Innovation Returns
- The Analytical Scientist, Oh, Elusive Innovation!, 2013 -- Oh, Elusive Innovation!
- The Medicine Maker, Advanced Therapies, Archaic Hardware: the Perils of Paper, 2024 -- Advanced Therapies, Archaic Hardware: the Perils of Paper
- the analytical scientist — Analytical Archimedes
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
- Selecting patients with sickle cell disease for gene addition or gene editing‐based therapeutic approaches
- EU CAR-T Handbook released to advance clinical practice and education
- ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
- SITC Immune Effector Cell-related Adverse Events Guideline - Society for Immunotherapy of Cancer (SITC)
- FACT and JACIE Co-Publish 9th Edition HCT Standards and 3rd Edition IEC Standards | EBMT
- Cellular & Gene Therapy Guidances | FDA
- FDA approves labeling changes that include a Boxed Warning for Immune Effector Cell-associated Enterocolitis following treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.) | FDA
- December 1, 2025 Clinical Review and Evaluation Memo - BREYANZI
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study | Journal of Clinical Oncology
- Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis - PubMed
- Exagamglogene Autotemcel for Severe Sickle Cell Disease | New England Journal of Medicine
- Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update | New England Journal of Medicine
- Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease | New England Journal of Medicine
Based on findings from:
Advanced Therapies: Invention or Innovation?
Liam Tremble. The Medicine Maker, 2026.
https://themedicinemaker.com/issues/2026/articles/september/advanced-therapies-invention-or-innovation/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
